董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Heidi Henson | 女 | Director | 60 | 未披露 | 未持股 | 2025-09-04 |
| Lori A. Woods | 女 | Chairperson, Director | 62 | 76.87万美元 | 未持股 | 2025-09-04 |
| Robert Froman Williamson, III | 男 | Director | 59 | 未披露 | 未持股 | 2025-09-04 |
| Frank Morich | 男 | Director | 71 | 未披露 | 未持股 | 2025-09-04 |
| Johan Spoor | 男 | Chief Executive Officer, Director | 53 | 未披露 | 未持股 | 2025-09-04 |
| Maya Martinez Davis | 女 | Director | -- | 未披露 | 未持股 | 2025-09-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joel Sendek | 男 | Chief Financial Officer | 58 | 未披露 | 未持股 | 2025-09-04 |
| Jonathan Hunt | 男 | Chief Accounting Officer | 58 | 未披露 | 未持股 | 2025-09-04 |
| Johan Spoor | 男 | Chief Executive Officer, Director | 53 | 未披露 | 未持股 | 2025-09-04 |
| Markus Puhlmann | 男 | Chief Medical Officer | 52 | 未披露 | 未持股 | 2025-09-04 |
董事简历
中英对照 | 中文 | 英文- Heidi Henson
-
Heidi Henson，自2015年3月合并起担任首席财务官兼秘书；2014年8月至2015年3月上游兼并期间担任 Prior Kura的首席财务官兼秘书；自2012年7月起担任Wellspring Biosciences LLC（私营生物制药公司，母公司是Araxes Pharma LLC）的首席财务官兼秘书；2007年至2012年3月间担任Intellikine, Inc.（私营生物制药公司）的财务副总裁，直至其被Takeda Pharmaceutical Company Limited收购。数年来，她是一名独立金融顾问，协助多家早期公司的启动活动、美国证券交易委员会报告、《萨班斯-奥克斯利法案（Sarbanes-Oxley）》的实施和遵守。她此前是Anadys Pharmaceuticals, Inc.（上市的生物制药公司）的财务主管，在Fair Isaac & Co., Inc.（前称HNC Software, Inc.， 上市软件公司）担任多项管理职位。她事业起步于在PricewaterhouseCoopers LLP（上市会计公司）的审计师经历，负责各类企业。她获得了San Diego大学的会计学学士学位，是一名注册会计师。
Heidi Henson,has been a director of the Company since June 1, 2023. Ms. Henson served as the Chief Financial Officer of Pardes Biosciences, Inc., a publicly listed biopharmaceutical company, from January 2021 until September 2023. Prior to that, she was a financial consultant for the same company from 2020 until her appointment as Chief Financial Officer. From 2019 through July 2020, she was the Chief Financial Officer of Imbria Pharmaceuticals, Inc., a private biopharmaceutical company. From 2018 through 2019, she was the Chief Financial Officer of Respivant Sciences, Inc., a private biopharmaceutical company. From 2014 through 2018, she was the Chief Financial Officer of Kura Oncology, Inc., a publicly listed biopharmaceuticals company. From 2012 through 2018, Ms. Henson was the Chief Financial Officer for Wellspring Biosciences LLC and Araxes Pharma LLC (its parent company), a private biopharmaceutical company. Ms. Henson currently serves on the board of directors of PepGen, Inc. (NASDAQ: PEPG) and Lisata Therapeutics, Inc. (NASDAQ: LSTA), both publicly traded, clinical-stage biotechnology companies, and she serves as the chair of both of their audit committees. Ms. Henson holds a Bachelor of Accountancy from the University of San Diego and is a Certified Public Accountant (inactive). - Heidi Henson，自2015年3月合并起担任首席财务官兼秘书；2014年8月至2015年3月上游兼并期间担任 Prior Kura的首席财务官兼秘书；自2012年7月起担任Wellspring Biosciences LLC（私营生物制药公司，母公司是Araxes Pharma LLC）的首席财务官兼秘书；2007年至2012年3月间担任Intellikine, Inc.（私营生物制药公司）的财务副总裁，直至其被Takeda Pharmaceutical Company Limited收购。数年来，她是一名独立金融顾问，协助多家早期公司的启动活动、美国证券交易委员会报告、《萨班斯-奥克斯利法案（Sarbanes-Oxley）》的实施和遵守。她此前是Anadys Pharmaceuticals, Inc.（上市的生物制药公司）的财务主管，在Fair Isaac & Co., Inc.（前称HNC Software, Inc.， 上市软件公司）担任多项管理职位。她事业起步于在PricewaterhouseCoopers LLP（上市会计公司）的审计师经历，负责各类企业。她获得了San Diego大学的会计学学士学位，是一名注册会计师。
- Heidi Henson,has been a director of the Company since June 1, 2023. Ms. Henson served as the Chief Financial Officer of Pardes Biosciences, Inc., a publicly listed biopharmaceutical company, from January 2021 until September 2023. Prior to that, she was a financial consultant for the same company from 2020 until her appointment as Chief Financial Officer. From 2019 through July 2020, she was the Chief Financial Officer of Imbria Pharmaceuticals, Inc., a private biopharmaceutical company. From 2018 through 2019, she was the Chief Financial Officer of Respivant Sciences, Inc., a private biopharmaceutical company. From 2014 through 2018, she was the Chief Financial Officer of Kura Oncology, Inc., a publicly listed biopharmaceuticals company. From 2012 through 2018, Ms. Henson was the Chief Financial Officer for Wellspring Biosciences LLC and Araxes Pharma LLC (its parent company), a private biopharmaceutical company. Ms. Henson currently serves on the board of directors of PepGen, Inc. (NASDAQ: PEPG) and Lisata Therapeutics, Inc. (NASDAQ: LSTA), both publicly traded, clinical-stage biotechnology companies, and she serves as the chair of both of their audit committees. Ms. Henson holds a Bachelor of Accountancy from the University of San Diego and is a Certified Public Accountant (inactive).
- Lori A. Woods
-
LoriA.Woods自2018年6月4日起担任公司董事。Woods女士在2006年至2008年2月担任Vice President之后回到Isoray，在2009年2月被任命为首席运营官之前，她被任命为代理首席运营官，一直担任到2010年1月。从2016年2月开始，Woods女士一直担任Isoray的高级顾问，直到2018年6月4日被任命为临时首席执行官。Woods女士于2018年12月12日被任命为公司首席执行官。2016年2月16日至2018年6月3日，Woods女士是Medvio，LLC（一家医疗设备咨询公司，专注于泌尿外科和肿瘤学领域）的创始人。任职Medvio公司期间，她曾任职大型公共和国际医疗设备公司，支持产品在多种国际市场的批准过程和分销。此外，她与各种合作伙伴一起为结肠直肠和肝脏治疗市场开发专有技术。此前，Woods从2002年1月到2006年7月担任Pro-Qura，Inc.（一家私营癌症治疗管理公司，专注于前列腺癌近距离治疗的质量交付）首席执行官。她也曾担任the Tumor Institute Radiation Oncology Group、西雅图前列腺研究所SPI（位于华盛顿州西雅图）的业务发展董事。SPI是前列腺近距离治疗的早期创新者，并协助培训了2000多名医生使用前列腺近距离治疗。Woods女士担任青少年糖尿病研究基金会（Juvenile Diabetes Research Foundation）西北分部的董事会成员，专注于他们的数字意识计划，包括他们的网站和SEO策略，以及他们的公关努力。Woods女士在加州洛玛琳达大学（Loma Linda University，CA）获得工商管理营销与传播理学学士学位。
Lori A. Woods,has been a Director of the Company since June 4, 2018, and has served as Chairperson of the Board since February 3, 2023. Most recently, Ms. Woods served as Chief Executive Officer of the Company from December 2018 to February 2023. Ms. Woods returned to the Company after previously serving as Vice President from 2006 to February 2008, at which time she was appointed Acting Chief Operating Officer before her appointment in February 2009 as Chief Operating Officer, a position she held until January 2010. Beginning in February 2016, and continuing until her appointment as Interim CEO on June 4, 2018, Ms. Woods served as a senior consultant to the Company. From February 2016 to June 2018, Ms. Woods was a founder of Medvio, LLC, a medical device consulting company focused on the urology and oncology space. During her time at Medvio she worked with large public and international medical device companies, supporting the approval process and distribution of products in diverse international markets. Further, she worked with various partners to develop proprietary technologies for the colorectal and liver treatment markets. Previously, from January 2002 to July 2006, Ms. Woods served as Chief Executive Officer of Pro-Qura, Inc., a privately owned cancer treatment management company focused on the quality delivery of brachytherapy treatments for prostate cancer. She has also served as the Director of Business Development for the Tumor Institute Radiation Oncology Group and the Seattle Prostate Institute ("SPI") in Seattle, WA. SPI was an early innovator in prostate brachytherapy treatments and assisted in the training of more than 2,000 physicians in the Perspective Therapeutics, Inc. e of prostate brachytherapy. Ms. Woods previously served as a board member of the Northwest division of the Juvenile Diabetes Research Foundation, focusing on their digital awareness programs, including their website and SEO strategy, and their public relations efforts. Ms. Woods earned a Bachelor of Science degree in Business Administration – Marketing and Communications from Loma Linda University, CA. - LoriA.Woods自2018年6月4日起担任公司董事。Woods女士在2006年至2008年2月担任Vice President之后回到Isoray，在2009年2月被任命为首席运营官之前，她被任命为代理首席运营官，一直担任到2010年1月。从2016年2月开始，Woods女士一直担任Isoray的高级顾问，直到2018年6月4日被任命为临时首席执行官。Woods女士于2018年12月12日被任命为公司首席执行官。2016年2月16日至2018年6月3日，Woods女士是Medvio，LLC（一家医疗设备咨询公司，专注于泌尿外科和肿瘤学领域）的创始人。任职Medvio公司期间，她曾任职大型公共和国际医疗设备公司，支持产品在多种国际市场的批准过程和分销。此外，她与各种合作伙伴一起为结肠直肠和肝脏治疗市场开发专有技术。此前，Woods从2002年1月到2006年7月担任Pro-Qura，Inc.（一家私营癌症治疗管理公司，专注于前列腺癌近距离治疗的质量交付）首席执行官。她也曾担任the Tumor Institute Radiation Oncology Group、西雅图前列腺研究所SPI（位于华盛顿州西雅图）的业务发展董事。SPI是前列腺近距离治疗的早期创新者，并协助培训了2000多名医生使用前列腺近距离治疗。Woods女士担任青少年糖尿病研究基金会（Juvenile Diabetes Research Foundation）西北分部的董事会成员，专注于他们的数字意识计划，包括他们的网站和SEO策略，以及他们的公关努力。Woods女士在加州洛玛琳达大学（Loma Linda University，CA）获得工商管理营销与传播理学学士学位。
- Lori A. Woods,has been a Director of the Company since June 4, 2018, and has served as Chairperson of the Board since February 3, 2023. Most recently, Ms. Woods served as Chief Executive Officer of the Company from December 2018 to February 2023. Ms. Woods returned to the Company after previously serving as Vice President from 2006 to February 2008, at which time she was appointed Acting Chief Operating Officer before her appointment in February 2009 as Chief Operating Officer, a position she held until January 2010. Beginning in February 2016, and continuing until her appointment as Interim CEO on June 4, 2018, Ms. Woods served as a senior consultant to the Company. From February 2016 to June 2018, Ms. Woods was a founder of Medvio, LLC, a medical device consulting company focused on the urology and oncology space. During her time at Medvio she worked with large public and international medical device companies, supporting the approval process and distribution of products in diverse international markets. Further, she worked with various partners to develop proprietary technologies for the colorectal and liver treatment markets. Previously, from January 2002 to July 2006, Ms. Woods served as Chief Executive Officer of Pro-Qura, Inc., a privately owned cancer treatment management company focused on the quality delivery of brachytherapy treatments for prostate cancer. She has also served as the Director of Business Development for the Tumor Institute Radiation Oncology Group and the Seattle Prostate Institute ("SPI") in Seattle, WA. SPI was an early innovator in prostate brachytherapy treatments and assisted in the training of more than 2,000 physicians in the Perspective Therapeutics, Inc. e of prostate brachytherapy. Ms. Woods previously served as a board member of the Northwest division of the Juvenile Diabetes Research Foundation, focusing on their digital awareness programs, including their website and SEO strategy, and their public relations efforts. Ms. Woods earned a Bachelor of Science degree in Business Administration – Marketing and Communications from Loma Linda University, CA.
- Robert Froman Williamson, III
-
Robert Froman Williamson，III，自2023年2月5日起担任本公司董事。Williamson先生被任命为与Viewpoint合并有关的董事。自2022年9月起，威廉森先生在细胞治疗公司Triumvira Immunologicals工作，最近担任总裁兼首席运营官，自2022年3月起担任蛋白质相互作用和降解剂公司SyntheX的高级顾问。2022年2月至9月，他担任溶瘤病毒公司OncoMyx的CBO/CFO。从2020年到2021年，他担任蛋白质降解疗法公司BioTheryX的首席执行官，筹集了1亿美元的交叉融资，并为该公司的IPO做准备。在此之前，威廉森曾于2013年至2019年担任PharmAkea的首席执行官，并于2019年担任ATXCo的首席执行官，这两家公司都是通过与Celgene的合作获得资金的肿瘤学和纤维化公司，直到PharmAkea于2019年被Galecto收购，ATXCo被Blade Therapeutics收购。在此之前，威廉森先生是Strategic Enzyme Applications的执行主席和创始人，Arriva Pharmaceuticals的首席执行官，Eos Biotechnology的总裁和首席运营官，该公司被出售给Protein Design Labs，DoubleTwist，Inc.通过被默沙东和日立收购而担任首席运营官。威廉森先生还在佛罗里达州迈阿密大学库尔特监督委员会任职，是一名合格的财务专家，并担任公司薪酬和审计委员会的主席。值得注意的是，威廉森先生曾担任Pharmasset, Inc.的早期董事，在那里，他帮助融资、发展和推动公司进入公开市场，并在2011年被吉利德以110亿美元收购。早些时候，威廉森是波士顿咨询集团的合伙人，也是联邦储备委员会的研究助理。威廉森在波莫纳学院获得经济学学士学位，在斯坦福大学获得MBA学位。
Robert Froman Williamson, III,has been a director of the Company since February 5, 2023. Mr. Williamson was appointed as a director in connection with the merger with Viewpoint. Since September 2022, Mr. Williamson has served in a number of roles at Triumvira Immunologicals, a private cell therapy company, most recently as Acting CEO, President, COO and Director. Since March 2022, he has also served as a senior adviser to SyntheX, a protein interaction and degrader company. From February to September 2022, he was the CBO/CFO of OncoMyx, an oncolytic virus company. From 2020 to 2021, he was CEO of BioTheryX, a protein degradation therapeutics company, raising a $100 million crossover round and preparing the company for an IPO. Prior to that, Mr. Williamson served as CEO of PharmAkea from 2013 to 2019, and of ATXCo in 2019, both oncology and fibrosis companies financed through a partnership with Celgene, until PharmAkea's acquisition by Galecto and ATXCo's acquisition by Blade Therapeutics, both in 2019. Previously, Mr. Williamson was Executive Chairman and founder of Strategic Enzyme Applications, CEO of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which was sold to Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi. Mr. Williamson also serves on the Coulter Oversight Board for the University of Miami, Florida, is a qualified financial expert and has chaired both the Audit Committee and the Compensation Committee of the Board (the "Compensation Committee"). Notably, Mr. Williamson served as an early Director of Pharmasset, Inc., where he helped finance, grow and advance the company into the public markets and through its acquisition by Gilead in 2011 for $11 billion. Earlier, Mr. Williamson was a Partner with The Boston Consulting Group and a Research Assistant for the Federal Reserve Board. Mr. Williamson received a BA in economics from Pomona College and an MBA from Stanford University. - Robert Froman Williamson，III，自2023年2月5日起担任本公司董事。Williamson先生被任命为与Viewpoint合并有关的董事。自2022年9月起，威廉森先生在细胞治疗公司Triumvira Immunologicals工作，最近担任总裁兼首席运营官，自2022年3月起担任蛋白质相互作用和降解剂公司SyntheX的高级顾问。2022年2月至9月，他担任溶瘤病毒公司OncoMyx的CBO/CFO。从2020年到2021年，他担任蛋白质降解疗法公司BioTheryX的首席执行官，筹集了1亿美元的交叉融资，并为该公司的IPO做准备。在此之前，威廉森曾于2013年至2019年担任PharmAkea的首席执行官，并于2019年担任ATXCo的首席执行官，这两家公司都是通过与Celgene的合作获得资金的肿瘤学和纤维化公司，直到PharmAkea于2019年被Galecto收购，ATXCo被Blade Therapeutics收购。在此之前，威廉森先生是Strategic Enzyme Applications的执行主席和创始人，Arriva Pharmaceuticals的首席执行官，Eos Biotechnology的总裁和首席运营官，该公司被出售给Protein Design Labs，DoubleTwist，Inc.通过被默沙东和日立收购而担任首席运营官。威廉森先生还在佛罗里达州迈阿密大学库尔特监督委员会任职，是一名合格的财务专家，并担任公司薪酬和审计委员会的主席。值得注意的是，威廉森先生曾担任Pharmasset, Inc.的早期董事，在那里，他帮助融资、发展和推动公司进入公开市场，并在2011年被吉利德以110亿美元收购。早些时候，威廉森是波士顿咨询集团的合伙人，也是联邦储备委员会的研究助理。威廉森在波莫纳学院获得经济学学士学位，在斯坦福大学获得MBA学位。
- Robert Froman Williamson, III,has been a director of the Company since February 5, 2023. Mr. Williamson was appointed as a director in connection with the merger with Viewpoint. Since September 2022, Mr. Williamson has served in a number of roles at Triumvira Immunologicals, a private cell therapy company, most recently as Acting CEO, President, COO and Director. Since March 2022, he has also served as a senior adviser to SyntheX, a protein interaction and degrader company. From February to September 2022, he was the CBO/CFO of OncoMyx, an oncolytic virus company. From 2020 to 2021, he was CEO of BioTheryX, a protein degradation therapeutics company, raising a $100 million crossover round and preparing the company for an IPO. Prior to that, Mr. Williamson served as CEO of PharmAkea from 2013 to 2019, and of ATXCo in 2019, both oncology and fibrosis companies financed through a partnership with Celgene, until PharmAkea's acquisition by Galecto and ATXCo's acquisition by Blade Therapeutics, both in 2019. Previously, Mr. Williamson was Executive Chairman and founder of Strategic Enzyme Applications, CEO of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which was sold to Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi. Mr. Williamson also serves on the Coulter Oversight Board for the University of Miami, Florida, is a qualified financial expert and has chaired both the Audit Committee and the Compensation Committee of the Board (the "Compensation Committee"). Notably, Mr. Williamson served as an early Director of Pharmasset, Inc., where he helped finance, grow and advance the company into the public markets and through its acquisition by Gilead in 2011 for $11 billion. Earlier, Mr. Williamson was a Partner with The Boston Consulting Group and a Research Assistant for the Federal Reserve Board. Mr. Williamson received a BA in economics from Pomona College and an MBA from Stanford University.
- Frank Morich
-
Frank Morich，自2023年2月5日起担任本公司董事。Morich博士被任命为与Viewpoint合并有关的董事。莫里奇博士于2021年2月至2023年2月3日担任Viewpoint的董事会成员。他还曾在位于马萨诸塞州波士顿的CUE-Biopharma担任董事会成员，该公司致力于蛋白质疗法，自2018年8月起应用于免疫肿瘤学、自身免疫和潜在的抗病毒应用，并自2021年4月起担任董事长。莫里奇博士是位于瑞士楚格的Aphaia Pharma的执行主席，该公司是一家临床阶段的生物制药公司，致力于治疗和预防肥胖和糖尿病等代谢紊乱，他自2022年6月起担任该职位。Morich博士于2015年至2021年担任MorphoSys的董事会成员，2004年至2010年担任Innate Pharma的董事会成员，这两家公司都是临床阶段的生物技术公司，专门从事抗体开发。在专注于董事会服务之前，Morich博士曾于2011年至2014年担任全球制药公司武田制药的首席商务官，并于2010年至2011年担任其国际业务执行副总裁。2008年至2010年，莫里奇博士担任临床阶段药物开发公司NOXXON Pharma AG的首席执行官，2005年至2007年，担任国际体外诊断公司Innogenetics N.V.的首席执行官和董事会成员。在此之前，Morich博士曾在拜耳担任多个职位，拜耳是一家全球性的制药和生命科学公司，包括拜耳公司管理委员会成员、全球产品开发主管和研发主管。Morich博士拥有马尔堡大学的医学博士和博士学位，专攻免疫学，专注于单克隆抗体。在进入私营部门之前，他还曾是一名军医。
Frank Morich,has been a director of the Company since February 5, 2023. Dr. Morich was appointed as a director in connection with the merger with Viewpoint. Dr. Morich served on the board of directors of Viewpoint from February 2021 until February 3, 2023. He has also served on the board of directors of CUE-Biopharma (NASDAQ: CUE), a company working on protein therapeutics with applications in immune-oncology, autoimmunity and potentially antiviral applications, since August 2018, and as its Chairman since April 2021. Dr. Morich also serves as Executive Chairman of Aphaia Pharma, a clinical-stage biopharmaceutical company working to treat and prevent metabolic disorders such as obesity and diabetes, a position he has held since June 2022. Dr. Morich served on the board of directors for MorphoSys from 2015 to 2021, and for Innate Pharma from 2004 to 2010, both clinical-stage biotechnology companies specializing in antibody development. Prior to focusing on board service, Dr. Morich was Chief Commercial Officer at Takeda Pharmaceuticals, a global pharmaceutical company, from 2011 to 2014, and Executive Vice President of International Operations from 2010 to 2011. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical-stage drug development company, and, from 2005 to 2007, as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including as a member of the Board of Management of Bayer AG, Head of Global Product Development, and Head of Research and Development. Dr. Morich holds an M.D. and Ph.D. from the University of Marburg where he specialized in immunology with a focus on monoclonal antibodies. He also served as a military physician before moving to the private sector. - Frank Morich，自2023年2月5日起担任本公司董事。Morich博士被任命为与Viewpoint合并有关的董事。莫里奇博士于2021年2月至2023年2月3日担任Viewpoint的董事会成员。他还曾在位于马萨诸塞州波士顿的CUE-Biopharma担任董事会成员，该公司致力于蛋白质疗法，自2018年8月起应用于免疫肿瘤学、自身免疫和潜在的抗病毒应用，并自2021年4月起担任董事长。莫里奇博士是位于瑞士楚格的Aphaia Pharma的执行主席，该公司是一家临床阶段的生物制药公司，致力于治疗和预防肥胖和糖尿病等代谢紊乱，他自2022年6月起担任该职位。Morich博士于2015年至2021年担任MorphoSys的董事会成员，2004年至2010年担任Innate Pharma的董事会成员，这两家公司都是临床阶段的生物技术公司，专门从事抗体开发。在专注于董事会服务之前，Morich博士曾于2011年至2014年担任全球制药公司武田制药的首席商务官，并于2010年至2011年担任其国际业务执行副总裁。2008年至2010年，莫里奇博士担任临床阶段药物开发公司NOXXON Pharma AG的首席执行官，2005年至2007年，担任国际体外诊断公司Innogenetics N.V.的首席执行官和董事会成员。在此之前，Morich博士曾在拜耳担任多个职位，拜耳是一家全球性的制药和生命科学公司，包括拜耳公司管理委员会成员、全球产品开发主管和研发主管。Morich博士拥有马尔堡大学的医学博士和博士学位，专攻免疫学，专注于单克隆抗体。在进入私营部门之前，他还曾是一名军医。
- Frank Morich,has been a director of the Company since February 5, 2023. Dr. Morich was appointed as a director in connection with the merger with Viewpoint. Dr. Morich served on the board of directors of Viewpoint from February 2021 until February 3, 2023. He has also served on the board of directors of CUE-Biopharma (NASDAQ: CUE), a company working on protein therapeutics with applications in immune-oncology, autoimmunity and potentially antiviral applications, since August 2018, and as its Chairman since April 2021. Dr. Morich also serves as Executive Chairman of Aphaia Pharma, a clinical-stage biopharmaceutical company working to treat and prevent metabolic disorders such as obesity and diabetes, a position he has held since June 2022. Dr. Morich served on the board of directors for MorphoSys from 2015 to 2021, and for Innate Pharma from 2004 to 2010, both clinical-stage biotechnology companies specializing in antibody development. Prior to focusing on board service, Dr. Morich was Chief Commercial Officer at Takeda Pharmaceuticals, a global pharmaceutical company, from 2011 to 2014, and Executive Vice President of International Operations from 2010 to 2011. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical-stage drug development company, and, from 2005 to 2007, as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including as a member of the Board of Management of Bayer AG, Head of Global Product Development, and Head of Research and Development. Dr. Morich holds an M.D. and Ph.D. from the University of Marburg where he specialized in immunology with a focus on monoclonal antibodies. He also served as a military physician before moving to the private sector.
- Johan Spoor
-
Johan Spoor，担任公司董事，自2023年2月5日起担任Perspective Therapeutics, Inc.首席执行官。Spoor先生因与Viewpoint Molecular Targeting，Inc.（“Viewpoint”）合并而被任命为董事。从2022年2月至2023年2月，斯普尔先生担任Viewpoint的首席执行官。在加入Viewpoint之前，从2019年10月到2021年6月，斯普尔先生担任KBP Biosciences的总裁兼首席执行官。KBP Biosciences是一家全球性的临床阶段生物技术公司，专注于发现、开发用于治疗严重心肾病和传染病的创新小分子疗法并将其商业化。在KBP Biosciences任职期间，斯普尔领导了主要筹资和首次公开募股（IPO）准备工作的所有业务，并推动了公司的小分子临床开发项目，包括毒理学、临床药理学、2期研究，以及与监管机构的讨论。在加入KBP BioSciences之前，从2016年1月到2019年10月，斯普尔先生担任AzurRx BioPharma公司的总裁兼首席执行官，领导了该公司在纳斯达克的首次公开发行，完成了动物研究、监管批准和多个2期研究。从2010年9月到2015年12月，斯普尔担任上市公司FluoroPharma Medical，Inc.的总裁兼首席执行官，并在奥纬咨询担任《财富》500强企业的健康和生命科学战略顾问。斯普尔曾在华尔街担任JP摩根和瑞士信贷的股票研究分析师，研究生物技术股票和医疗设备公司。他的职业生涯始于核药学方面的正式培训，这使他在GE Healthcare（Amersham）的心脏病学和肿瘤学领域的影像业务中担任越来越多的商业领导角色。斯普尔先生也是Verifi Water公司的董事会成员。斯普尔先生拥有多伦多大学的药学学位和哥伦比亚商学院的MBA学位。
Johan Spoor,has been a director of the Company and has served as Chief Executive Officer since February 5, 2023. Mr. Spoor was appointed as a director in connection with the merger with Viewpoint Molecular Targeting, Inc. ("Viewpoint"). From February 2022 until February 2023, Mr. Spoor served as a director as well as the President and the Chief Executive Officer of Viewpoint. Prior to joining Viewpoint, from October 2019 until June 2021, Mr. Spoor served as the President and CEO of KBP Biosciences, a global, clinical-stage biotechnology company focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases. While at KBP Biosciences, Mr. Spoor led all operations for major fund-raising and initial public offering ("IPO") readiness, and drove the company's small molecule clinical development programs, including toxicology, clinical pharmacology, Phase 2 studies, and discussions with regulators. Prior to KBP BioSciences, from January 2016 until October 2019, Mr. Spoor served as the President and CEO of AzurRx BioPharma, Inc., where he led its Nasdaq IPO, completion of animal studies, regulatory approvals and multiple Phase 2 studies. Mr. Spoor previously served on the board of directors of Verifi Water, Inc. from 2017 through 2023. From September 2010 until December 2015, Mr. Spoor served as the President and CEO of FluoroPharma Medical, Inc., which he took public. He was previously a Health and Life Sciences strategy consultant to Fortune 500 companies at Oliver Wyman. Mr. Spoor previously worked on Wall Street as an equity research analyst at JP Morgan and Credit Suisse where he covered biotechnology stocks and medical device companies. He started his career with formal training in nuclear pharmacy which led to increasing commercial leadership roles in the imaging business at GE Healthcare (Amersham) in cardiology and oncology. Mr. Spoor holds a Pharmacy degree from the University of Toronto and an MBA from Columbia Business School. - Johan Spoor，担任公司董事，自2023年2月5日起担任Perspective Therapeutics, Inc.首席执行官。Spoor先生因与Viewpoint Molecular Targeting，Inc.（“Viewpoint”）合并而被任命为董事。从2022年2月至2023年2月，斯普尔先生担任Viewpoint的首席执行官。在加入Viewpoint之前，从2019年10月到2021年6月，斯普尔先生担任KBP Biosciences的总裁兼首席执行官。KBP Biosciences是一家全球性的临床阶段生物技术公司，专注于发现、开发用于治疗严重心肾病和传染病的创新小分子疗法并将其商业化。在KBP Biosciences任职期间，斯普尔领导了主要筹资和首次公开募股（IPO）准备工作的所有业务，并推动了公司的小分子临床开发项目，包括毒理学、临床药理学、2期研究，以及与监管机构的讨论。在加入KBP BioSciences之前，从2016年1月到2019年10月，斯普尔先生担任AzurRx BioPharma公司的总裁兼首席执行官，领导了该公司在纳斯达克的首次公开发行，完成了动物研究、监管批准和多个2期研究。从2010年9月到2015年12月，斯普尔担任上市公司FluoroPharma Medical，Inc.的总裁兼首席执行官，并在奥纬咨询担任《财富》500强企业的健康和生命科学战略顾问。斯普尔曾在华尔街担任JP摩根和瑞士信贷的股票研究分析师，研究生物技术股票和医疗设备公司。他的职业生涯始于核药学方面的正式培训，这使他在GE Healthcare（Amersham）的心脏病学和肿瘤学领域的影像业务中担任越来越多的商业领导角色。斯普尔先生也是Verifi Water公司的董事会成员。斯普尔先生拥有多伦多大学的药学学位和哥伦比亚商学院的MBA学位。
- Johan Spoor,has been a director of the Company and has served as Chief Executive Officer since February 5, 2023. Mr. Spoor was appointed as a director in connection with the merger with Viewpoint Molecular Targeting, Inc. ("Viewpoint"). From February 2022 until February 2023, Mr. Spoor served as a director as well as the President and the Chief Executive Officer of Viewpoint. Prior to joining Viewpoint, from October 2019 until June 2021, Mr. Spoor served as the President and CEO of KBP Biosciences, a global, clinical-stage biotechnology company focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases. While at KBP Biosciences, Mr. Spoor led all operations for major fund-raising and initial public offering ("IPO") readiness, and drove the company's small molecule clinical development programs, including toxicology, clinical pharmacology, Phase 2 studies, and discussions with regulators. Prior to KBP BioSciences, from January 2016 until October 2019, Mr. Spoor served as the President and CEO of AzurRx BioPharma, Inc., where he led its Nasdaq IPO, completion of animal studies, regulatory approvals and multiple Phase 2 studies. Mr. Spoor previously served on the board of directors of Verifi Water, Inc. from 2017 through 2023. From September 2010 until December 2015, Mr. Spoor served as the President and CEO of FluoroPharma Medical, Inc., which he took public. He was previously a Health and Life Sciences strategy consultant to Fortune 500 companies at Oliver Wyman. Mr. Spoor previously worked on Wall Street as an equity research analyst at JP Morgan and Credit Suisse where he covered biotechnology stocks and medical device companies. He started his career with formal training in nuclear pharmacy which led to increasing commercial leadership roles in the imaging business at GE Healthcare (Amersham) in cardiology and oncology. Mr. Spoor holds a Pharmacy degree from the University of Toronto and an MBA from Columbia Business School.
- Maya Martinez Davis
-
Maya Martinez Davis，目前担任GSK美国商业业务总裁，自2019年9月起担任该职位。在担任这一职务期间，她领导着专业、呼吸、肿瘤和疫苗领域强大而复杂的产品业务组合。在加入GSK之前，Martinez-Davis女士于2018年4月至2019年8月在默沙东 KGaA担任生物制药拉丁美洲总裁，在此之前于2016年1月至2018年3月担任其生物制药业务的高级副总裁兼全球肿瘤学主管。在加入默沙东之前，她曾在辉瑞公司工作，2003年至2015年在肿瘤学、疫苗和专科组合领域任职，其中包括十多年的高级主管职务。此外，Martinez-Davis女士在2018年至2024年1月被Bristol Myers Squibb收购之前一直担任Mirati Therapeutics, Inc.的董事会成员，该公司是一家临床阶段的生物技术公司，专注于靶向肿瘤疗法的开发。Martinez-Davis女士拥有圣路易斯大学的本科学位和西班牙马德里IE商业学院的商业领导和市场营销硕士学位。
Maya Martinez Davis currently serves as President of GSK's U.S. Commercial biness, a position she has held since September 2019. In that role, she leads a robt and complex biness portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin America at Merck KGaA, from April 2018 to Augt 2019, and prior to that served as Senior Vice President and Head of Global Oncology for its biopharma biness from January 2016 through March 2018. Prior to joining Merck, she worked at Pfizer, Inc., from 2003 to 2015 in the areas of oncology, vaccines and specialty portfolios, including over a decade in senior executive roles. In addition, Ms. Martinez-Davis served on the Board of Directors of Mirati Therapeutics, Inc., a clinical-stage biotechnology company foced on the development of targeted oncology therapies, from 2018 until its acquisition by Bristol Myers Squibb in January 2024. Ms. Martinez-Davis holds an undergraduate degree from Saint Louis University and a Master's in biness leadership and marketing from the IE Biness Institute in Madrid, Spain. - Maya Martinez Davis，目前担任GSK美国商业业务总裁，自2019年9月起担任该职位。在担任这一职务期间，她领导着专业、呼吸、肿瘤和疫苗领域强大而复杂的产品业务组合。在加入GSK之前，Martinez-Davis女士于2018年4月至2019年8月在默沙东 KGaA担任生物制药拉丁美洲总裁，在此之前于2016年1月至2018年3月担任其生物制药业务的高级副总裁兼全球肿瘤学主管。在加入默沙东之前，她曾在辉瑞公司工作，2003年至2015年在肿瘤学、疫苗和专科组合领域任职，其中包括十多年的高级主管职务。此外，Martinez-Davis女士在2018年至2024年1月被Bristol Myers Squibb收购之前一直担任Mirati Therapeutics, Inc.的董事会成员，该公司是一家临床阶段的生物技术公司，专注于靶向肿瘤疗法的开发。Martinez-Davis女士拥有圣路易斯大学的本科学位和西班牙马德里IE商业学院的商业领导和市场营销硕士学位。
- Maya Martinez Davis currently serves as President of GSK's U.S. Commercial biness, a position she has held since September 2019. In that role, she leads a robt and complex biness portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin America at Merck KGaA, from April 2018 to Augt 2019, and prior to that served as Senior Vice President and Head of Global Oncology for its biopharma biness from January 2016 through March 2018. Prior to joining Merck, she worked at Pfizer, Inc., from 2003 to 2015 in the areas of oncology, vaccines and specialty portfolios, including over a decade in senior executive roles. In addition, Ms. Martinez-Davis served on the Board of Directors of Mirati Therapeutics, Inc., a clinical-stage biotechnology company foced on the development of targeted oncology therapies, from 2018 until its acquisition by Bristol Myers Squibb in January 2024. Ms. Martinez-Davis holds an undergraduate degree from Saint Louis University and a Master's in biness leadership and marketing from the IE Biness Institute in Madrid, Spain.
高管简历
中英对照 | 中文 | 英文- Joel Sendek
Joel Sendek，在生命科学领域拥有超过30年的经验，包括在四家生命科学公司担任首席财务官以及担任覆盖生物技术领域的高级卖方研究分析师。在加入公司之前，Sendek先生于2022年8月至2025年9月担任全球经纪和投资银行Oppenheimer & Co. Inc.的董事总经理兼医疗保健生命科学研究主管。在加入Oppenheimer之前，他曾在四家公司担任首席财务官职务，包括2021年1月至2022年7月的私营生物技术公司Dewpoint Therapeutics、2019年11月至2021年1月的私营健康情报公司Sema4、2017年5月至2019年11月的上市生物制药公司Spero治疗以及2014年8月至2017年4月的私营生物制药公司Forward Pharma A/S。在担任首席财务官职务之前，他于2012年1月至2014年7月在Stifel Financial Corp.担任董事总经理，领导该公司的医疗保健股票研究小组；于2000年1月至2011年10月在Lazard担任董事总经理，在那里他建立并领导了该公司的医疗保健股票研究工作。在从事股票研究职业之前，Sendek先生曾在Progenics Pharmaceuticals, Inc.担任企业发展高级总监，并在Goldman, Sachs & Co.担任投资银行分析师。Sendek先生拥有Rice大学生物化学学士学位。
Joel Sendek,has over 30 years of experience in the life sciences sector, including as a Chief Financial Officer at four life sciences companies and as a senior sell-side research analyst covering the biotechnology sector. Prior to joining the Company, Mr. Sendek was Managing Director and Head of Healthcare Life Sciences Research at Oppenheimer & Co. Inc., a global brokerage and investment bank, from August 2022 to September 2025. Prior to Oppenheimer, he held Chief Financial Officer roles at four companies, including Dewpoint Therapeutics, a private biotechnology company, from January 2021 to July 2022, Sema4, a private health intelligence company, from November 2019 to January 2021, Spero Therapeutics, a publicly traded biopharmaceutical company, from May 2017 to November 2019, and Forward Pharma A/S, a private biopharmaceutical company, from August 2014 to April 2017. Prior to his Chief Financial Officer roles, he served as a Managing Director at Stifel Financial Corp. from January 2012 to July 2014, where he led that firm's healthcare equity research group, and as Managing Director at Lazard from January 2000 to October 2011, where he established and led that firm's healthcare equity research effort. Prior to his career in equity research, Mr. Sendek worked as Senior Director of Corporate Development at Progenics Pharmaceuticals, Inc. and as an investment banking analyst at Goldman, Sachs & Co. Mr. Sendek holds a B.A. in Biochemistry from Rice University.- Joel Sendek，在生命科学领域拥有超过30年的经验，包括在四家生命科学公司担任首席财务官以及担任覆盖生物技术领域的高级卖方研究分析师。在加入公司之前，Sendek先生于2022年8月至2025年9月担任全球经纪和投资银行Oppenheimer & Co. Inc.的董事总经理兼医疗保健生命科学研究主管。在加入Oppenheimer之前，他曾在四家公司担任首席财务官职务，包括2021年1月至2022年7月的私营生物技术公司Dewpoint Therapeutics、2019年11月至2021年1月的私营健康情报公司Sema4、2017年5月至2019年11月的上市生物制药公司Spero治疗以及2014年8月至2017年4月的私营生物制药公司Forward Pharma A/S。在担任首席财务官职务之前，他于2012年1月至2014年7月在Stifel Financial Corp.担任董事总经理，领导该公司的医疗保健股票研究小组；于2000年1月至2011年10月在Lazard担任董事总经理，在那里他建立并领导了该公司的医疗保健股票研究工作。在从事股票研究职业之前，Sendek先生曾在Progenics Pharmaceuticals, Inc.担任企业发展高级总监，并在Goldman, Sachs & Co.担任投资银行分析师。Sendek先生拥有Rice大学生物化学学士学位。
- Joel Sendek,has over 30 years of experience in the life sciences sector, including as a Chief Financial Officer at four life sciences companies and as a senior sell-side research analyst covering the biotechnology sector. Prior to joining the Company, Mr. Sendek was Managing Director and Head of Healthcare Life Sciences Research at Oppenheimer & Co. Inc., a global brokerage and investment bank, from August 2022 to September 2025. Prior to Oppenheimer, he held Chief Financial Officer roles at four companies, including Dewpoint Therapeutics, a private biotechnology company, from January 2021 to July 2022, Sema4, a private health intelligence company, from November 2019 to January 2021, Spero Therapeutics, a publicly traded biopharmaceutical company, from May 2017 to November 2019, and Forward Pharma A/S, a private biopharmaceutical company, from August 2014 to April 2017. Prior to his Chief Financial Officer roles, he served as a Managing Director at Stifel Financial Corp. from January 2012 to July 2014, where he led that firm's healthcare equity research group, and as Managing Director at Lazard from January 2000 to October 2011, where he established and led that firm's healthcare equity research effort. Prior to his career in equity research, Mr. Sendek worked as Senior Director of Corporate Development at Progenics Pharmaceuticals, Inc. and as an investment banking analyst at Goldman, Sachs & Co. Mr. Sendek holds a B.A. in Biochemistry from Rice University.
- Jonathan Hunt
Jonathan Hunt于2018年12月3日被任命为公司首席财务官。2019年2月12日，亨特先生被任命为联席首席财务官。在加入该公司之前，亨特曾于2009年至2018年在在线安全培训公司Vivid Learning Systems担任首席财务官，在该公司的转型过程中，他发挥了核心作用，包括不断增长的收入以及实施最终导致成功出售业务的财务政策和流程变更。亨特先生曾于2006年至2009年担任该公司首席财务官。在此之前，Hunt先生曾在Hypercom Corporation公司（一家全球电子支付解决方案提供商和信用卡终端制造商）工作，在那里他从2005年到2006年担任公司财务总监助理。Hunt先生拥有杨百翰大学（Brigham Young University）的理学士学位、会计学学士学位和会计学硕士学位。
Jonathan Hunt,has served as the Company's Chief Accounting Officer since August 16, 2024. He also served as the Company's Chief Financial Officer from December 3, 2018 until January 6, 2025 and as Co-Principal Financial Officer from February 12, 2019 until January 6, 2025. Before joining the Company, Mr. Hunt was Chief Financial Officer at Vivid Learning Systems, an online safety training company, from 2009 to 2018, where he had a central role in its turnaround, including growing revenues and implementing financial policy and process changes that ultimately resulted in the successful sale of the business. Mr. Hunt previously served as Chief Financial Officer of the Company from 2006 to 2009. Prior to that, Mr. Hunt worked at Hypercom Corporation, a global provider of electronic payment solutions and manufacturer of credit card terminals, where he served as Assistant Corporate Controller from 2005 to 2006. Mr. Hunt holds a Bachelor of Science, Accountancy, and a Masters of Accountancy degree from Brigham Young University.- Jonathan Hunt于2018年12月3日被任命为公司首席财务官。2019年2月12日，亨特先生被任命为联席首席财务官。在加入该公司之前，亨特曾于2009年至2018年在在线安全培训公司Vivid Learning Systems担任首席财务官，在该公司的转型过程中，他发挥了核心作用，包括不断增长的收入以及实施最终导致成功出售业务的财务政策和流程变更。亨特先生曾于2006年至2009年担任该公司首席财务官。在此之前，Hunt先生曾在Hypercom Corporation公司（一家全球电子支付解决方案提供商和信用卡终端制造商）工作，在那里他从2005年到2006年担任公司财务总监助理。Hunt先生拥有杨百翰大学（Brigham Young University）的理学士学位、会计学学士学位和会计学硕士学位。
- Jonathan Hunt,has served as the Company's Chief Accounting Officer since August 16, 2024. He also served as the Company's Chief Financial Officer from December 3, 2018 until January 6, 2025 and as Co-Principal Financial Officer from February 12, 2019 until January 6, 2025. Before joining the Company, Mr. Hunt was Chief Financial Officer at Vivid Learning Systems, an online safety training company, from 2009 to 2018, where he had a central role in its turnaround, including growing revenues and implementing financial policy and process changes that ultimately resulted in the successful sale of the business. Mr. Hunt previously served as Chief Financial Officer of the Company from 2006 to 2009. Prior to that, Mr. Hunt worked at Hypercom Corporation, a global provider of electronic payment solutions and manufacturer of credit card terminals, where he served as Assistant Corporate Controller from 2005 to 2006. Mr. Hunt holds a Bachelor of Science, Accountancy, and a Masters of Accountancy degree from Brigham Young University.
- Johan Spoor
Johan Spoor，担任公司董事，自2023年2月5日起担任Perspective Therapeutics, Inc.首席执行官。Spoor先生因与Viewpoint Molecular Targeting，Inc.（“Viewpoint”）合并而被任命为董事。从2022年2月至2023年2月，斯普尔先生担任Viewpoint的首席执行官。在加入Viewpoint之前，从2019年10月到2021年6月，斯普尔先生担任KBP Biosciences的总裁兼首席执行官。KBP Biosciences是一家全球性的临床阶段生物技术公司，专注于发现、开发用于治疗严重心肾病和传染病的创新小分子疗法并将其商业化。在KBP Biosciences任职期间，斯普尔领导了主要筹资和首次公开募股（IPO）准备工作的所有业务，并推动了公司的小分子临床开发项目，包括毒理学、临床药理学、2期研究，以及与监管机构的讨论。在加入KBP BioSciences之前，从2016年1月到2019年10月，斯普尔先生担任AzurRx BioPharma公司的总裁兼首席执行官，领导了该公司在纳斯达克的首次公开发行，完成了动物研究、监管批准和多个2期研究。从2010年9月到2015年12月，斯普尔担任上市公司FluoroPharma Medical，Inc.的总裁兼首席执行官，并在奥纬咨询担任《财富》500强企业的健康和生命科学战略顾问。斯普尔曾在华尔街担任JP摩根和瑞士信贷的股票研究分析师，研究生物技术股票和医疗设备公司。他的职业生涯始于核药学方面的正式培训，这使他在GE Healthcare（Amersham）的心脏病学和肿瘤学领域的影像业务中担任越来越多的商业领导角色。斯普尔先生也是Verifi Water公司的董事会成员。斯普尔先生拥有多伦多大学的药学学位和哥伦比亚商学院的MBA学位。
Johan Spoor,has been a director of the Company and has served as Chief Executive Officer since February 5, 2023. Mr. Spoor was appointed as a director in connection with the merger with Viewpoint Molecular Targeting, Inc. ("Viewpoint"). From February 2022 until February 2023, Mr. Spoor served as a director as well as the President and the Chief Executive Officer of Viewpoint. Prior to joining Viewpoint, from October 2019 until June 2021, Mr. Spoor served as the President and CEO of KBP Biosciences, a global, clinical-stage biotechnology company focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases. While at KBP Biosciences, Mr. Spoor led all operations for major fund-raising and initial public offering ("IPO") readiness, and drove the company's small molecule clinical development programs, including toxicology, clinical pharmacology, Phase 2 studies, and discussions with regulators. Prior to KBP BioSciences, from January 2016 until October 2019, Mr. Spoor served as the President and CEO of AzurRx BioPharma, Inc., where he led its Nasdaq IPO, completion of animal studies, regulatory approvals and multiple Phase 2 studies. Mr. Spoor previously served on the board of directors of Verifi Water, Inc. from 2017 through 2023. From September 2010 until December 2015, Mr. Spoor served as the President and CEO of FluoroPharma Medical, Inc., which he took public. He was previously a Health and Life Sciences strategy consultant to Fortune 500 companies at Oliver Wyman. Mr. Spoor previously worked on Wall Street as an equity research analyst at JP Morgan and Credit Suisse where he covered biotechnology stocks and medical device companies. He started his career with formal training in nuclear pharmacy which led to increasing commercial leadership roles in the imaging business at GE Healthcare (Amersham) in cardiology and oncology. Mr. Spoor holds a Pharmacy degree from the University of Toronto and an MBA from Columbia Business School.- Johan Spoor，担任公司董事，自2023年2月5日起担任Perspective Therapeutics, Inc.首席执行官。Spoor先生因与Viewpoint Molecular Targeting，Inc.（“Viewpoint”）合并而被任命为董事。从2022年2月至2023年2月，斯普尔先生担任Viewpoint的首席执行官。在加入Viewpoint之前，从2019年10月到2021年6月，斯普尔先生担任KBP Biosciences的总裁兼首席执行官。KBP Biosciences是一家全球性的临床阶段生物技术公司，专注于发现、开发用于治疗严重心肾病和传染病的创新小分子疗法并将其商业化。在KBP Biosciences任职期间，斯普尔领导了主要筹资和首次公开募股（IPO）准备工作的所有业务，并推动了公司的小分子临床开发项目，包括毒理学、临床药理学、2期研究，以及与监管机构的讨论。在加入KBP BioSciences之前，从2016年1月到2019年10月，斯普尔先生担任AzurRx BioPharma公司的总裁兼首席执行官，领导了该公司在纳斯达克的首次公开发行，完成了动物研究、监管批准和多个2期研究。从2010年9月到2015年12月，斯普尔担任上市公司FluoroPharma Medical，Inc.的总裁兼首席执行官，并在奥纬咨询担任《财富》500强企业的健康和生命科学战略顾问。斯普尔曾在华尔街担任JP摩根和瑞士信贷的股票研究分析师，研究生物技术股票和医疗设备公司。他的职业生涯始于核药学方面的正式培训，这使他在GE Healthcare（Amersham）的心脏病学和肿瘤学领域的影像业务中担任越来越多的商业领导角色。斯普尔先生也是Verifi Water公司的董事会成员。斯普尔先生拥有多伦多大学的药学学位和哥伦比亚商学院的MBA学位。
- Johan Spoor,has been a director of the Company and has served as Chief Executive Officer since February 5, 2023. Mr. Spoor was appointed as a director in connection with the merger with Viewpoint Molecular Targeting, Inc. ("Viewpoint"). From February 2022 until February 2023, Mr. Spoor served as a director as well as the President and the Chief Executive Officer of Viewpoint. Prior to joining Viewpoint, from October 2019 until June 2021, Mr. Spoor served as the President and CEO of KBP Biosciences, a global, clinical-stage biotechnology company focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases. While at KBP Biosciences, Mr. Spoor led all operations for major fund-raising and initial public offering ("IPO") readiness, and drove the company's small molecule clinical development programs, including toxicology, clinical pharmacology, Phase 2 studies, and discussions with regulators. Prior to KBP BioSciences, from January 2016 until October 2019, Mr. Spoor served as the President and CEO of AzurRx BioPharma, Inc., where he led its Nasdaq IPO, completion of animal studies, regulatory approvals and multiple Phase 2 studies. Mr. Spoor previously served on the board of directors of Verifi Water, Inc. from 2017 through 2023. From September 2010 until December 2015, Mr. Spoor served as the President and CEO of FluoroPharma Medical, Inc., which he took public. He was previously a Health and Life Sciences strategy consultant to Fortune 500 companies at Oliver Wyman. Mr. Spoor previously worked on Wall Street as an equity research analyst at JP Morgan and Credit Suisse where he covered biotechnology stocks and medical device companies. He started his career with formal training in nuclear pharmacy which led to increasing commercial leadership roles in the imaging business at GE Healthcare (Amersham) in cardiology and oncology. Mr. Spoor holds a Pharmacy degree from the University of Toronto and an MBA from Columbia Business School.
- Markus Puhlmann
Markus Puhlmann，自2023年2月3日起担任Perspective Therapeutics首席医疗官。普尔曼博士是一名临床研究人员，在医疗保健和制药行业拥有30多年的综合经验，在肿瘤药物开发领域担任领导职务，该领域涉及所有临床开发阶段的实体和液体肿瘤适应症。在加入Perspective Therapeutics之前，Puhlmann博士曾在2019年至2022年担任Seagen CD30特许经营全球临床开发主管，在那里他建立了一些项目，探索ADC对各种肿瘤和非肿瘤适应症的免疫调节特性。在加入Seagen之前，普尔曼博士于2015年至2019年加入默沙东公司，从事帕博利珠单抗的临床开发工作。在启动pembrolizumab GYN项目后，Puhlmann博士专注于GU适应症的扩展，并开发了一个广泛的试验组合。在此职位上，Puhlmann博士领导并促成了pembrolizumab在尿路上皮癌、RCC和宫颈癌等不同适应症的许多成功监管申报。此外，Puhlmann博士领导了默沙东与EISAI合作的临床开发项目。在他职业生涯的早期，他曾在先灵葆雅、拜耳和安进担任过多个职位，并在临床开发和医疗事务方面承担了越来越多的责任。普尔曼博士还在NIH的NCI外科部门工作了六年，在那里他研究了自杀基因治疗方法，包括细胞因子对肿瘤新生血管系统的影响。普尔曼博士曾在英国和德国接受外科医生培训，拥有德国慕尼黑路德维希马克西米利安大学的医学学位，以及乔治城大学麦克多诺商学院的EMBA学位。
Markus Puhlmann,has served as the Chief Medical Officer of Perspective Therapeutics since February 5, 2023, prior to which he served as the Chief Medical Officer of Viewpoint beginning in October 2022. Dr. Puhlmann is a clinical researcher with over 30 years of combined experience in healthcare and the pharmaceutical industry with leadership positions in oncology drug development for solid and liquid tumor indications involving all phases of clinical development. Before joining Viewpoint, Dr. Puhlmann served as the CD30 Franchise Head of Global Clinical Development at Seagen (NASDAQ: SGEN) from 2019 to 2022, where he built programs to explore the immune modulating properties of antibody-drug conjugates for various oncology and non-oncology indications. Prior to his time at Seagen, Dr. Puhlmann worked at Merck & Co on the clinical development of pembrolizumab from 2015 to 2019. After initiating the pembrolizumab gynecological program, Dr. Puhlmann focused on the expansion of genitourinary indications and developed an extensive trial portfolio. In this capacity, Dr. Puhlmann led and contributed to many successful regulatory filings for pembrolizumab across different indications such as urothelial carcinoma, renal cell carcinoma and cervical cancer. In addition, Dr. Puhlmann led the clinical development program for the collaboration of the partnership between Merck and EISAI. Earlier in his career, he held various positions with increasing responsibilities in clinical development and medical affairs at Schering Plough, Bayer and Amgen. Dr. Puhlmann also spent six years at the Surgery Branch, NCI, NIH, where he researched suicide gene therapy approaches including the effects of cytokines on tumor neovasculature. Dr. Puhlmann trained as a surgeon in the UK and Germany and holds a medical degree from the Ludwig Maximilians University, Munich, Germany as well as an Executive MBA from Georgetown's McDonough School of Business.- Markus Puhlmann，自2023年2月3日起担任Perspective Therapeutics首席医疗官。普尔曼博士是一名临床研究人员，在医疗保健和制药行业拥有30多年的综合经验，在肿瘤药物开发领域担任领导职务，该领域涉及所有临床开发阶段的实体和液体肿瘤适应症。在加入Perspective Therapeutics之前，Puhlmann博士曾在2019年至2022年担任Seagen CD30特许经营全球临床开发主管，在那里他建立了一些项目，探索ADC对各种肿瘤和非肿瘤适应症的免疫调节特性。在加入Seagen之前，普尔曼博士于2015年至2019年加入默沙东公司，从事帕博利珠单抗的临床开发工作。在启动pembrolizumab GYN项目后，Puhlmann博士专注于GU适应症的扩展，并开发了一个广泛的试验组合。在此职位上，Puhlmann博士领导并促成了pembrolizumab在尿路上皮癌、RCC和宫颈癌等不同适应症的许多成功监管申报。此外，Puhlmann博士领导了默沙东与EISAI合作的临床开发项目。在他职业生涯的早期，他曾在先灵葆雅、拜耳和安进担任过多个职位，并在临床开发和医疗事务方面承担了越来越多的责任。普尔曼博士还在NIH的NCI外科部门工作了六年，在那里他研究了自杀基因治疗方法，包括细胞因子对肿瘤新生血管系统的影响。普尔曼博士曾在英国和德国接受外科医生培训，拥有德国慕尼黑路德维希马克西米利安大学的医学学位，以及乔治城大学麦克多诺商学院的EMBA学位。
- Markus Puhlmann,has served as the Chief Medical Officer of Perspective Therapeutics since February 5, 2023, prior to which he served as the Chief Medical Officer of Viewpoint beginning in October 2022. Dr. Puhlmann is a clinical researcher with over 30 years of combined experience in healthcare and the pharmaceutical industry with leadership positions in oncology drug development for solid and liquid tumor indications involving all phases of clinical development. Before joining Viewpoint, Dr. Puhlmann served as the CD30 Franchise Head of Global Clinical Development at Seagen (NASDAQ: SGEN) from 2019 to 2022, where he built programs to explore the immune modulating properties of antibody-drug conjugates for various oncology and non-oncology indications. Prior to his time at Seagen, Dr. Puhlmann worked at Merck & Co on the clinical development of pembrolizumab from 2015 to 2019. After initiating the pembrolizumab gynecological program, Dr. Puhlmann focused on the expansion of genitourinary indications and developed an extensive trial portfolio. In this capacity, Dr. Puhlmann led and contributed to many successful regulatory filings for pembrolizumab across different indications such as urothelial carcinoma, renal cell carcinoma and cervical cancer. In addition, Dr. Puhlmann led the clinical development program for the collaboration of the partnership between Merck and EISAI. Earlier in his career, he held various positions with increasing responsibilities in clinical development and medical affairs at Schering Plough, Bayer and Amgen. Dr. Puhlmann also spent six years at the Surgery Branch, NCI, NIH, where he researched suicide gene therapy approaches including the effects of cytokines on tumor neovasculature. Dr. Puhlmann trained as a surgeon in the UK and Germany and holds a medical degree from the Ludwig Maximilians University, Munich, Germany as well as an Executive MBA from Georgetown's McDonough School of Business.